Bayer

Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Thursday, March 14, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

BERLIN, March 14, 2024 (GLOBE NEWSWIRE) -- Bayer and Aignostics GmbH today announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Under the terms of the agreement, the companies will collaborate on multiple discovery programs and initiate at least two target identification programs.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Development, Gene editing, Growth, Regeneron Pharmaceuticals, Biotechnology, Science and nature, Merck Serono, Patient, Branches of microbiology, Acquisition, Virology, Executive Committee, Max Planck Society, CRISPR Therapeutics, University, Senior, Bayer, Publication, Therapy, Takeda, CRISPR, Amgen, CRSP, Medicine, Pharmaceutical industry

“We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.

Key Points: 
  • “We are thrilled to welcome Christian to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
  • Dr. Rommel currently serves as Executive Vice President, Global Head of Research & Development and a Member of the Executive Committee of Bayer Pharmaceuticals, Inc.
  • He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED).
  • He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor of 18 patents.

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CDMO, Novartis, Regulatory affairs, CGMP, Bayer, KBI, Chemical engineering, Multimedia, Amgen, Rensselaer Polytechnic Institute, Engineering

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
  • Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
  • "We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D.
  • "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers.

Global Immune Health Supplements Outlook Report 2024: Market to Reach $34.73 Billion by 2028 with Amway, Bayer, DSM, Glanbia, Herbalife Nutrition, and Nutramax Laboratories Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2024
Vitamins, Supplements, Health, Capsule, Dicarboxylic acid, Attention, Bayer, Vitamin, Growth, Prevalence, Vitamin D, Infection, Amway, Dietary supplement, Printing, Probiotic, COVID-19, Zinc, DSM, Tablet, Calcium, Pharmacy, Selenium, Ageing, Pregnancy, Mineral, Protein, Mineral deficiency, Woman, Nutritional science, Immunity, Wound healing, Iron, Nutraceutical, Herbalife, Herbal, Supermarket

The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%

Key Points: 
  • The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach $34.73 billion by 2028, growing at a CAGR of 8.92%
    The global immune health supplements market is witnessing several dynamic changes after the Coronavirus surge worldwide.
  • In the global immune health supplements market, several leading domestic, national, and international vendors are present.
  • North America accounted for the highest global immune health supplements market share, accounting for over 33% in 2022.
  • High Demand for Immune Health Supplements with Zinc, Vitamin C & D, and Curcumins
    In the immune health supplements market, vitamin C, vitamin D, zinc, and curcumins are the most used and suggested ingredients for immune health.

Xcell Biosciences Announces New Scientific and Business Advisory Board

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Technology, Health, General Health, Oncology, Health Technology, Research, Software, Artificial Intelligence, Genetics, Science, PCR, Organization, EWF, Prostate cancer, Juno Therapeutics, Synthetic biology, Trex, University, CBO, Jak, Biology, Bayer, Investment, Therapy, Mountaineering, Intergalactic, AVATAR, SUGEN, Hematology, Bio-Rad Laboratories, Medicine

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.

Key Points: 
  • Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
  • The board will provide valuable expertise to help the company achieve its goals in the therapeutics market.
  • Prior to Affini-T, Jak was head of health venture investments for Leaps by Bayer, a leading corporate venture fund.
  • Jak also served as CEO of CytoSen Therapeutics, where he developed natural killer immune cell therapies for oncology indications.

Noetik Appoints Dr. Shafique Virani as Chief Business Officer

Retrieved on: 
Wednesday, March 27, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Recursion, Neuromyelitis optica spectrum disorder, University, Drug discovery, Patient, Cancer, Medicine, Doctor of Philosophy, Bayer, Therapy, COA, Machine learning, CSO, Multimedia, Pharmaceutical industry

Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.

Key Points: 
  • Noetik , an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240327236059/en/
    "We are thrilled to welcome Shaf to our team as Chief Business Officer.
  • Prior to joining Noetik, Dr. Virani served as Recursion’s Chief Corporate Development Officer, as well as the interim Chief Medical Officer as part of his tenure.
  • As Chief Business Officer, Dr. Virani will accelerate Noetik’s mission through both business development and portfolio strategy by identifying and facilitating strategically impactful transactions.

Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Aromatherapy, National Consumers League, Hydrocodone, MAPDA, NCL, Partnership, Mother, Education, Patient, Yoga, Paracetamol, Opioid use disorder, Naproxen, Trial of the century, Bayer, Meditation, OTC, CDC, Love, Pain, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240325938118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325938118/en/
    Aleve launches "The Painful Truth" campaign with Mothers Against Prescription Drug Abuse (MAPDA) and National Consumers League (NCL).
  • (Photo: Business Wire)
    While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries.
  • “The Painful Truth” campaign launches with a three-minute film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance.
  • At this critical juncture in their care, the patients are encouraged to consider different pain relief options.

TaskUs and V7 Announce Strategic Partnership To Enable Enterprise AI Product Delivery

Retrieved on: 
Monday, March 25, 2024
Software, Technology, Artificial Intelligence, Data Management, Concept, Organization, Pressure, Health, Partnership, Fintech, SVP, Roche, GDPR, Social media, Merck, Miele, Bayer, Lawyer, Automated machine learning, Sony, DICOM, Production, Sales

TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.

Key Points: 
  • TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.
  • With a proven track record in supporting enterprise retail, healthcare, and asset management industries, the collaboration between V7 and TaskUs offers customers accelerated training data delivery, reduced production costs, and turnkey enterprise solutions.
  • The partnership aims to slash development cycles and enable enterprises to launch AI products significantly faster.
  • "We are thrilled about our strategic partnership with V7, marking a transformative phase in AI product development,” said Phil Tomlinson, SVP, of Global Offerings at TaskUs.

Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Fitness & Nutrition, Growth, Digital, Bayer, Oncology, Global marketing, Management

Bayer’s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused.

Key Points: 
  • Bayer’s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused.
  • In this role, Guth will work with teams across countries and regions to drive the commercial strategy to enhance customer value, maximize market opportunities, and generate revenue growth and profitability for Bayer pharmaceuticals around the world.
  • Guth will continue to report to Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceutical Division.
  • “These changes within our Leadership Team reflect this new approach to realize the full potential of our growth opportunities.”

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.